Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVTXNASDAQ:CNCENASDAQ:MBIONASDAQ:OTIC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$14.98+5.5%$9.19$3.95▼$1,130.40$15.43M1.15543,295 shs160,863 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AMBIOMustang Bio$0.36+2.9%$0.94$0.32▼$8.17$3.71M1.58176,325 shs63,965 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/A(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+5.49%+24.73%+214.71%+236.63%-97.93%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MBIOMustang Bio+2.11%-3.64%-61.60%-75.00%-90.81%OTICOtonomy0.00%0.00%0.00%0.00%0.00%A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio2.3954 of 5 stars3.55.00.00.03.30.00.0OTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics2.50Moderate BuyN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AMBIOMustang Bio3.00Buy$17.254,725.17% UpsideOTICOtonomyN/AN/AN/AN/ACurrent Analyst RatingsLatest AVTX, MBIO, CNCE, and OTIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024AVTXAvalo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$1.92M8.04N/AN/A$9.11 per share1.64CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$31.54M-$616.67N/AN/AN/A-1,639.50%-1,439.87%-113.95%5/2/2024 (Estimated)CNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AMBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ALatest AVTX, MBIO, CNCE, and OTIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A1.821.82CNCEConcert PharmaceuticalsN/A9.039.03MBIOMustang BioN/A0.740.74OTICOtonomyN/A1.741.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%CNCEConcert Pharmaceuticals70.63%MBIOMustang Bio9.95%OTICOtonomy41.23%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.20%CNCEConcert Pharmaceuticals11.33%MBIOMustang Bio2.10%OTICOtonomy1.09%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics191.03 million1.03 millionNot OptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableOTICOtonomy5168.53 million67.78 millionOptionableAVTX, MBIO, CNCE, and OTIC HeadlinesSourceHeadlineTop 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023straight.com - April 21 at 9:08 PMAllergic Contact Dermatitis and Topical Antibioticsmedscape.com - September 10 at 4:13 PMHearing Loss in Adultsnejm.org - August 21 at 11:30 PMResearch Publicationsslu.edu - August 4 at 7:44 PMManagement of Pediatric Otitis Mediamedscape.com - May 11 at 11:26 PMHearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPRnews.google.com - May 8 at 10:11 AMAlluvial Capital Management Q1 2023 Letter To Partners - Seeking Alphanews.google.com - April 28 at 7:44 AMVertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital Journalnews.google.com - April 27 at 9:58 AMHearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPRnews.google.com - April 25 at 4:57 PMENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital Journalnews.google.com - April 24 at 7:52 AMHearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital Journalnews.google.com - April 11 at 10:37 PMENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital Journalnews.google.com - April 10 at 7:51 AM[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital Journalnews.google.com - April 10 at 7:51 AMHearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital Journalnews.google.com - April 3 at 7:09 PMHearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints Newsnews.google.com - March 30 at 1:22 PMAlector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMMathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMBoehringer reports robust sales led by type 2 diabetes and ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMSeelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints Newsnews.google.com - March 30 at 8:21 AMSpiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to ... - PR Newswirenews.google.com - March 29 at 8:47 PMSpiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear ... - BioSpacenews.google.com - March 29 at 10:46 AMOtic Drug Market Size Historical Growth, Analysis, Opportunities and Forecast To 2029| Pediapharm Novus Therap - openPRnews.google.com - March 27 at 9:52 AMHearing Loss Pipeline Drugs and Companies Insight Report, 2023 ... - Digital Journalnews.google.com - March 23 at 9:50 AMHearing Loss Disease Treatment Market 2023 key developmental ... - openPRnews.google.com - March 22 at 6:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvalo TherapeuticsNASDAQ:AVTXAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Concert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.OtonomyNASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.